Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F13%3A10209795" target="_blank" >RIV/00216208:11130/13:10209795 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s00262-012-1342-1" target="_blank" >http://dx.doi.org/10.1007/s00262-012-1342-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00262-012-1342-1" target="_blank" >10.1007/s00262-012-1342-1</a>
Alternative languages
Result language
angličtina
Original language name
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Original language description
Inhibitor of apoptosis proteins (IAPs) are critical in regulating apoptosis resistance in cancer. Antagonists of IAPs, such as LCL161, are in clinical development and show promise as anti-cancer agents for solid and hematological cancers, with preliminary data suggesting they may act as immunomodulators. IAP antagonists hypersensitize tumor cells to TNF-alpha-mediated apoptosis, an effect that may work in synergy with that of cancer vaccines. This study aimed to further investigate the immunomodulatoryproperties of LCL161 on human immune subsets. T lymphocytes treated with LCL161 demonstrated significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhanced priming of na < ve T cells with synthetic peptides in vitro. Myeloid dendritic cells underwent phenotypic maturation upon IAP antagonism and demonstrated a reduced capacity to cross-present a tu
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT12402" target="_blank" >NT12402: Dendritic cell based cancer immunotherapy of ovarian cancer Phase I/II clinical trial</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Immunology, Immunotherapy
ISSN
0340-7004
e-ISSN
—
Volume of the periodical
62
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
15
Pages from-to
321-335
UT code for WoS article
000314768500011
EID of the result in the Scopus database
—